drugset / Trial / NCT05441631

Can Intensive Insulin Therapy Improve Outcomes of COVID-19 Patients

NCT05441631

Phase 1 Completed 436 enrolled Benha University
RandomizedParallel-groupSingle-blindTreatment

Summary

Evaluation of the reciprocal relation between hyperglycemia/diabetes mellitus (HG/DM) and COVID-19 disease and the effect of mode of insulin therapy; intensive (IIT) or conventional (CIT) on patients' outcomes All patients admitted to the quarantine hospitals with mild-severe COVID disease were evaluated using the COVID-GRAM Critical Illness Risk Score and gave blood samples for estimation of random blood glucose. Diabetic patients and non-diabetic patients with persistent HG were randomly divided according to mode of IT. Patients who were free HG were included as control normoglycemic (NG) patients. Study outcomes included the incidence of progress to critical illness and mortality rate (MR), and the effect of IT on such outcomes

Timeline

Start
2020-04-01
Primary completion
2020-07-15
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic Subcutaneous

Indications